---
title: Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER )
nct_id: NCT06731244
overall_status: RECRUITING
phase: NA
sponsor: University Hospital, Brest
study_type: INTERVENTIONAL
primary_condition: Venous Thromboembolism
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06731244.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06731244"
ct_last_update_post_date: 2025-11-28
last_seen_at: "2026-05-12T06:35:11.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER )

**Official Title:** Prognosis Improvement of Unprovoked vEnous THromboEmbolism With the Use of a Shared Decision-making Process Including a Time-dependent Multicomponent Risk Prediction Scores inteRvention.

**NCT ID:** [NCT06731244](https://clinicaltrials.gov/study/NCT06731244)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 2400
- **Lead Sponsor:** University Hospital, Brest
- **Collaborators:** European Commission, European Clinical Research Infrastructure Network
- **Conditions:** Venous Thromboembolism
- **Start Date:** 2025-10-30
- **Completion Date:** 2035-10
- **CT.gov Last Update:** 2025-11-28

## Brief Summary

Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) is a frequent disease and the third most common cause of cardiovascular death in the world after myocardial infarction and stroke. Anticoagulant therapy drastically reduces the risk of early VTE recurrence and death, but it exposes patients to a substantial risk of bleeding. Hence, determining the optimal duration of anticoagulant treatment for VTE is a major public health issue.

When major transient risk factors for VTE are identified (major surgery, immobilization...), patients generally do not need to extend anticoagulation beyond 3 months, whereas for VTE diagnosed in the context of cancer, therapeutic anticoagulation is required for as long as the cancer is considered "active".

However, in more than 50% of cases, venous thromboembolic disease occurs spontaneously, i.e. without any significant clinically detectable circumstance (known as unprovoked venous thromboembolic disease). In such patients, the risk of recurrence is high (35% recurrence rate at 5 years, with a 10% risk of death per recurrence). Scientific societies therefore recommend continuing anticoagulant treatment "indefinitely" (i.e. without programming a stop date or long-term treatment). However, this practice exposes these patients to an ongoing, non-negligible increase in the risk of bleeding, which could ultimately exceed the risk of recurrence of venous thrombo-embolic disease.

Optimizing anticoagulant therapy beyond the first three to six months of treatment is therefore a crucial and challenging issue, which could improve the long-term prognosis of patients with unprovoked thromboembolic venous disease.

Based on the quantitative and qualitative approaches implemented in MORPHEUS project granted by European Commission (HORIZON-HLTH-2022-TOOL-11-01 call), the investigators have combined predictive personalized medicine, through the use of risk biomarkers, with a patient-centered model of medicine, which, while based on an understanding of the patient's experience, leading to develop Time-Dependent Multicomponent risk prediction scores and socIo-anthropological scales (TDMI) integrated in a shared decision-making process regarding anticoagulant treatment duration in patients with a first episode of unprovoked VTE.

The aim of this study is to demonstrate that this strategy, based on a medical decision-making process shared between patients and physicians and including TDMI, reduces the risk of recurrence of thromboembolic venous disease (fatal or non-fatal), the risk of bleeding and all-cause mortality, and is associated with greater patient satisfaction after a first episode of unprovoked thromboembolic venous disease.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patient \> or = 18 years,
* Patient with a first episode of symptomatic unprovoked pulmonary embolism (PE) and/or proximal deep vein thrombosis (DVT) treated for 3 to 6 uninterrupted months with full dose anticoagulant therapy,
* Signed informed consent.

Exclusion Criteria:

* Unable or refusal to give informed consent,
* Isolated distal DVT,
* Isolated sub-segmental PE
* Previous unprovoked VTE
* Known CTEPH
* Indication for anticoagulation other than DVT or PE (e.g.; atrial fibrillation, mechanic valves…),
* Interruption of anticoagulation for 14 days or more before the inclusion,
* Active cancer of less than 24 months,
* Current pregnancy,
* Life expectancy \<18 months (e.g.; patients with an end-stage chronic disease)
* Not affiliated to national insurance, social security (only for France)
```

## Arms

- **Control arm** (ACTIVE_COMPARATOR) — Anticoagulant treatment management according to usual practice and international guidelines
- **Experimental arm** (EXPERIMENTAL) — Shared decision-making process integrating time-dependent multicomponent risk prediction scores and socio-anthropological scales (TDMI)

## Interventions

- **Usual Care Group** (OTHER) — Patients will be managed as regards their anticoagulant treatment according to usual practice and in accordance with international guidelines.
- **shared decision-making process** (OTHER) — The intervention is based on a strategy based on a shared decision-making process which is a collaborative process that involves a patient and their healthcare professional working together to reach a joint decision about care (anticoagulant treatment).

The shared decision-making process will be conducted as follows:

* Step 1: prepare the risk estimates (risk of recurrent VTE, risk of bleeding) for the patient, based on time-dependent multicomponent risk prediction scores and socio-anthropological scales (TDMI) and other validated risk prediction scores and evidence-based medicine;
* Step 2: Communicating risks, benefits and consequences to the patient;
* Step 3: Make a joint decision about treatment and care, and agree together when this will be reviewed.

## Primary Outcomes

- **Hierarchical composite of adjudicated all-cause mortality, adjudicated symptomatic recurrent VTE (fatal or non-fatal PE or proximal DVT), adjudicated major and clinically relevant non-major bleeding, and patient's satisfaction** _(time frame: From inclusion to 18th month follow-up)_ — For the statistical analysis, the investigators will analyse hierarchically each component of the composite (all-cause mortality, then VTE recurrence, then major bleeding or clinically relevant non-major bleeding and then patient's satisfaction in this order) using a win ratio approach to assess the primary composite outcome.

## Secondary Outcomes

- **Composite of adjudicated all-cause mortality, symptomatic recurrent VTE (fatal or non-fatal PE or proximal DVT) and major and clinically relevant non-major bleeding** _(time frame: At 18-month follow-up after inclusion)_
- **Adjudicated all-cause mortality,** _(time frame: At 18 months follow-up after inclusion)_
- **Adjudicated symptomatic VTE recurrence** _(time frame: At 18-month follow-up after inclusion)_
- **Adjudicated major bleeding or clinically relevant non-major bleeding** _(time frame: At 18-month follow-up after inclusion)_
- **Adjudicated fatal recurrent VTE and fatal bleeding** _(time frame: At 18-month follow-up after inclusion)_
- **Patient's satisfaction** _(time frame: At 18-month follow-up after inclusion)_
- **Quality of life (QoL) assessed using PembQoL questionnaire** _(time frame: At 18 months after inclusion)_
- **Quality of life (QoL) assessed using mMRC dyspnea score** _(time frame: At 18 months after inclusion)_
- **Quality of life (QoL) assessed using VEINQol questionnaire** _(time frame: At 18 months after inclusion)_
- **Quality of life (QoL) assessed using Villalta score** _(time frame: At 18 months after inclusion)_
- **Quality of life (QoL) assessed using EQ-5D5L questionnaire** _(time frame: At 18 months after inclusion)_
- **Quality of life (QoL) assessed using PVFS scale patients** _(time frame: At 18 months after inclusion)_
- **Therapeutic adherence to anticoagulant treatment** _(time frame: At18-month follow-up after inclusion)_
- **Occurence of objectively diagnosed cancer: site, localized, locally advanced, metastatic** _(time frame: From inclusion to 18th months follow-up)_
- **Occurence of minor or atypical venous thrombosis** _(time frame: At 18-month follow-up after inclusion)_
- **Adjudicated objectively diagnosed acute arterial thromboembolic events according to international guidelines: stroke, myocardial infarction, peripheral arterial thromboembolic event, atrial fibrillation, any cardiac event other than VTE** _(time frame: At 18-month follow-up after inclusion)_
- **Adjudicated objectively confirmed chronic thromboembolic pulmonary disease and chronic thromboembolic pulmonary hypertension** _(time frame: At 18-month follow-up after inclusion)_

## Locations (20)

- CHU Brest, Brest, France, France — _RECRUITING_
- CHU d'Amiens - Picardie, Amiens, France — _NOT_YET_RECRUITING_
- CHU d'Angers, Angers, France — _NOT_YET_RECRUITING_
- Hôpital National d'Instruction des Armées Percy, Clamart, France — _NOT_YET_RECRUITING_
- CHU de Clermont Ferrand, Clermont-Ferrand, France — _NOT_YET_RECRUITING_
- APHP-Colombes, Colombes, France — _NOT_YET_RECRUITING_
- CHU de Dijon - Hôpital François Mitterand, Dijon, France — _NOT_YET_RECRUITING_
- CH Le Mans, Le Mans, France — _NOT_YET_RECRUITING_
- HCL - Hôpital Edouard Herriot, Lyon, France — _NOT_YET_RECRUITING_
- APHM - Hôpital la Timone, Marseille, France — _NOT_YET_RECRUITING_
- CHU de Montpellier, Montpellier, France — _NOT_YET_RECRUITING_
- CHU de Nancy, Nancy, France — _NOT_YET_RECRUITING_
- CHU de Nantes, Nantes, France — _NOT_YET_RECRUITING_
- CHU de Nîmes, Nîmes, France — _NOT_YET_RECRUITING_
- Aphp-Hegp, Paris, France — _NOT_YET_RECRUITING_
- Aphp-Hegp, Paris, France — _NOT_YET_RECRUITING_
- CHU de Rennes, Rennes, France — _NOT_YET_RECRUITING_
- CHU Saint Etienne, Saint-Etienne, France — _NOT_YET_RECRUITING_
- CHU de Strasbourg, Strasbourg, France — _NOT_YET_RECRUITING_
- CHU de Toulouse, Toulouse, France — _NOT_YET_RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chu brest|brest|france|france` — added _(2026-05-12)_
- `locations.chu d'amiens - picardie|amiens||france` — added _(2026-05-12)_
- `locations.chu d'angers|angers||france` — added _(2026-05-12)_
- `locations.hôpital national d'instruction des armées percy|clamart||france` — added _(2026-05-12)_
- `locations.chu de clermont ferrand|clermont-ferrand||france` — added _(2026-05-12)_
- `locations.aphp-colombes|colombes||france` — added _(2026-05-12)_
- `locations.chu de dijon - hôpital françois mitterand|dijon||france` — added _(2026-05-12)_
- `locations.ch le mans|le mans||france` — added _(2026-05-12)_
- `locations.hcl - hôpital edouard herriot|lyon||france` — added _(2026-05-12)_
- `locations.aphm - hôpital la timone|marseille||france` — added _(2026-05-12)_
- `locations.chu de montpellier|montpellier||france` — added _(2026-05-12)_
- `locations.chu de nancy|nancy||france` — added _(2026-05-12)_
- `locations.chu de nantes|nantes||france` — added _(2026-05-12)_
- `locations.chu de nîmes|nîmes||france` — added _(2026-05-12)_
- `locations.aphp-hegp|paris||france` — added _(2026-05-12)_
- `locations.chu de rennes|rennes||france` — added _(2026-05-12)_
- `locations.chu saint etienne|saint-etienne||france` — added _(2026-05-12)_
- `locations.chu de strasbourg|strasbourg||france` — added _(2026-05-12)_
- `locations.chu de toulouse|toulouse||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06731244.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06731244*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*